AR076445A1 - Regeneracion de islotes pancreaticos y reversion de la diabetes por medio de la administracion in vivo de genes del factor de transcripcion de los islotes. composicion. metodo. vector. celula. - Google Patents
Regeneracion de islotes pancreaticos y reversion de la diabetes por medio de la administracion in vivo de genes del factor de transcripcion de los islotes. composicion. metodo. vector. celula.Info
- Publication number
- AR076445A1 AR076445A1 ARP090104420A ARP090104420A AR076445A1 AR 076445 A1 AR076445 A1 AR 076445A1 AR P090104420 A ARP090104420 A AR P090104420A AR P090104420 A ARP090104420 A AR P090104420A AR 076445 A1 AR076445 A1 AR 076445A1
- Authority
- AR
- Argentina
- Prior art keywords
- insulin
- composition
- exon
- promoter
- pancreas
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 8
- 108090000623 proteins and genes Proteins 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 2
- 206010012601 diabetes mellitus Diseases 0.000 title 1
- 230000008929 regeneration Effects 0.000 title 1
- 238000011069 regeneration method Methods 0.000 title 1
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 40
- 108090001061 Insulin Proteins 0.000 abstract 23
- 102000004877 Insulin Human genes 0.000 abstract 20
- 229940125396 insulin Drugs 0.000 abstract 20
- 108020004707 nucleic acids Proteins 0.000 abstract 10
- 150000007523 nucleic acids Chemical class 0.000 abstract 10
- 102000039446 nucleic acids Human genes 0.000 abstract 10
- 230000006378 damage Effects 0.000 abstract 8
- 108050000588 Neurogenic differentiation factor 1 Proteins 0.000 abstract 7
- 210000004027 cell Anatomy 0.000 abstract 7
- 210000000496 pancreas Anatomy 0.000 abstract 7
- 108700039691 Genetic Promoter Regions Proteins 0.000 abstract 5
- 239000002502 liposome Substances 0.000 abstract 5
- 108091026898 Leader sequence (mRNA) Proteins 0.000 abstract 4
- 102100032063 Neurogenic differentiation factor 1 Human genes 0.000 abstract 4
- 108700005075 Regulator Genes Proteins 0.000 abstract 4
- 239000012634 fragment Substances 0.000 abstract 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 3
- 102100024458 Cyclin-dependent kinase inhibitor 2A Human genes 0.000 abstract 2
- 108090000266 Cyclin-dependent kinases Proteins 0.000 abstract 2
- 102000003903 Cyclin-dependent kinases Human genes 0.000 abstract 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 2
- 239000008280 blood Substances 0.000 abstract 2
- 210000004369 blood Anatomy 0.000 abstract 2
- 239000008103 glucose Substances 0.000 abstract 2
- 238000002604 ultrasonography Methods 0.000 abstract 2
- HMLGSIZOMSVISS-ONJSNURVSA-N (7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2,2-dimethylpropanoyloxymethoxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound N([C@@H]1C(N2C(=C(C=C)CSC21)C(O)=O)=O)C(=O)\C(=N/OCOC(=O)C(C)(C)C)C1=CSC(N)=N1 HMLGSIZOMSVISS-ONJSNURVSA-N 0.000 abstract 1
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 abstract 1
- 102400001242 Betacellulin Human genes 0.000 abstract 1
- 101800001382 Betacellulin Proteins 0.000 abstract 1
- 108050006400 Cyclin Proteins 0.000 abstract 1
- 102000016736 Cyclin Human genes 0.000 abstract 1
- 102000006312 Cyclin D2 Human genes 0.000 abstract 1
- 108010058544 Cyclin D2 Proteins 0.000 abstract 1
- 101100129232 Danio rerio mafaa gene Proteins 0.000 abstract 1
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 abstract 1
- 102100025101 GATA-type zinc finger protein 1 Human genes 0.000 abstract 1
- 102400000322 Glucagon-like peptide 1 Human genes 0.000 abstract 1
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 abstract 1
- 108700040460 Hexokinases Proteins 0.000 abstract 1
- 108091016366 Histone-lysine N-methyltransferase EHMT1 Proteins 0.000 abstract 1
- 108700014808 Homeobox Protein Nkx-2.2 Proteins 0.000 abstract 1
- 102100028098 Homeobox protein Nkx-6.1 Human genes 0.000 abstract 1
- 101000980932 Homo sapiens Cyclin-dependent kinase inhibitor 2A Proteins 0.000 abstract 1
- 101000578254 Homo sapiens Homeobox protein Nkx-6.1 Proteins 0.000 abstract 1
- 101000603702 Homo sapiens Neurogenin-3 Proteins 0.000 abstract 1
- 101000613495 Homo sapiens Paired box protein Pax-4 Proteins 0.000 abstract 1
- 101000733249 Homo sapiens Tumor suppressor ARF Proteins 0.000 abstract 1
- 102000051628 Interleukin-1 receptor antagonist Human genes 0.000 abstract 1
- 108700021006 Interleukin-1 receptor antagonist Proteins 0.000 abstract 1
- 229940118135 JNK inhibitor Drugs 0.000 abstract 1
- 239000012825 JNK inhibitor Substances 0.000 abstract 1
- 101150051019 Klrg1 gene Proteins 0.000 abstract 1
- 101150084866 MAFA gene Proteins 0.000 abstract 1
- 102100038553 Neurogenin-3 Human genes 0.000 abstract 1
- 102100040909 Paired box protein Pax-4 Human genes 0.000 abstract 1
- 102100041030 Pancreas/duodenum homeobox protein 1 Human genes 0.000 abstract 1
- 239000004952 Polyamide Substances 0.000 abstract 1
- 101710183548 Pyridoxal 5'-phosphate synthase subunit PdxS Proteins 0.000 abstract 1
- 108020004459 Small interfering RNA Proteins 0.000 abstract 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 abstract 1
- 229960004238 anakinra Drugs 0.000 abstract 1
- 230000002424 anti-apoptotic effect Effects 0.000 abstract 1
- 229940121363 anti-inflammatory agent Drugs 0.000 abstract 1
- 239000002260 anti-inflammatory agent Substances 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 150000002632 lipids Chemical class 0.000 abstract 1
- -1 lsI1 Proteins 0.000 abstract 1
- 239000013612 plasmid Substances 0.000 abstract 1
- 229920002647 polyamide Polymers 0.000 abstract 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 abstract 1
- 230000001172 regenerating effect Effects 0.000 abstract 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 abstract 1
- 229960002930 sirolimus Drugs 0.000 abstract 1
- 229960001967 tacrolimus Drugs 0.000 abstract 1
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0028—Disruption, e.g. by heat or ultrasounds, sonophysical or sonochemical activation, e.g. thermosensitive or heat-sensitive liposomes, disruption of calculi with a medicinal preparation and ultrasounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0083—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the administration regime
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Plant Pathology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Dispersion Chemistry (AREA)
- Cell Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Reivindicacion 1: Una composicion para la destruccion de microburbujas dirigida por ultrasonido en el páncreas, caracterizada porque comprende un complejo preensamblado de liposomas y ácidos nucleicos en microburbujas, donde el complejo preensamblado de liposomas y ácidos nucleicos comprende un gen NeuroD bajo el control de un promotor de insulina, que comprende uno o más genes reguladores que responden a la insulina, unidos operativamente a una region promotora de la insulina que comprende un fragmento genomico del promotor de la insulina que comprende una region no traducida 5', el exon 1, el intron 1 y el exon 2 del gen de la insulina, donde la destruccion de la microburbuja en un sitio blanco en el páncreas permite introducir el ácido nucleico en las células del páncreas en las que ha tenido lugar dicha destruccion dirigida por ultrasonido, donde las células en las que se ha incorporado el ácido nucleico expresan insulina en respuesta a los niveles elevados de glucosa en la sangre. Reivindicacion 3: La composicion de la reivindicacion 1, caracterizada porque también comprende uno o más genes seleccionados entre uno o más genes reguladores que responden a la insulina, unidos operativamente a una region promotora de la insulina seleccionada entre ngn3, GLP1, PDX1, Mafa, la betacelulina, Nkx2.2, Nkx6.1, PAX4, lsI1, la ciclina D2 (y otros miembros de la familia de la ciclina), CDK4 (y otros miembros de la familia de la quinasa dependiente de ciclina) y ARNpi contra inhibidores de la quinasa dependientes de ciclina, tales como p16 y otros miembros de la familia INK4 o p27 y otros miembros de la familia CIP/KIP. Reivindicacion 4: La composicion de la reivindicacion 1, caracterizada porque también comprende un agente que se co-administra con la composicion, donde el agente se selecciona entre un agente anti-apoptotico, un agente antiinflamatorio, un inhibidor de JNK, un GLP-1, un tacrolimus, un sirolimus, una anakinra, una poliamida de Dervin o combinaciones de éstos. Reivindicacion 5: Una composicion para regenerar células beta pancreáticas por medio de la destruccion de microburbujas dirigida por ultrasonido en el páncreas, caracterizada porque comprende microburbujas que comprenden NeuroD, donde las microburbujas comprenden lípidos que liberan NeuroD mediante la destruccion dirigida por ultrasonido en el páncreas. Reivindicacion 7: La composicion de la reivindicacion 5, caracterizada porque NeuroD comprende un gen NeuroD bajo el control de un promotor CUBI, RIP2.1, RIP3.1 o HIP3.1, y donde NeuroD se expresa en las células donde se desea la expresion por medio de la destruccion de microburbujas dirigida por ultrasonido. Reivindicacion 25: Un ácido nucleico aislado caracterizado porque comprende una region promotora de la insulina que comprende un fragmento genomico del promotor de la insulina que comprende una region no traducida 5', el exon 1, el intron 1 y el exon 2 del gen de la insulina, hacia el extremo 5' de uno o más genes que responden a al insulina. Reivindicacion 32: La composicion de la reivindicacion 26, caracterizada porque el complejo preensamblado de liposomas y ácidos nucleicos comprende 1,2- dipalmitoil-sn-glicero-3-fosfatidilcolina y 1,2-dipalmitoil-sn-glicero-3-fosfatidiletanolamina glicerol en combinacion con un plásmido. Reivindicacion 35: Un vector caracterizado porque comprende un gen de hexoquinasa bajo el control de un promotor que comprende uno o más genes reguladores que responden a la insulina, unidos operativamente a una region promotora de la insulina que comprende un fragmento genomico del promotor de la insulina que comprende una region no traducida 5', el exon 1, el intron 1 y el exon 2 del gen de la insulina. Reivindicacion 41: Una célula caracterizada porque se le ha conferido la capacidad de responder a la insulina con un método que comprende inyectar en una célula un complejo preensamblado de liposomas y ácidos nucleicos en una microburbuja, donde el complejo preensamblado de liposomas y ácidos nucleicos comprende un gen NeuroD bajo el control de un promotor de insulina que comprende uno o más genes reguladores que responden a la insulina, unidos operativamente a una region promotora de la insulina que comprende un fragmento genomico del promotor de la insulina que comprende una region no traducida 5', el exon 1, el intron 1 y el exon 2 del gen de la insulina, donde la destruccion de la microburbuja en un sitio blanco en el páncreas permite introducir el ácido nucleico en las células del páncreas en las que ha tenido lugar dicha destruccion dirigida por ultrasonido, donde las células en las que se ha incorporado el ácido nucleico expresan insulina en respuesta a los niveles elevados de glucosa en la sangre.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11440708P | 2008-11-13 | 2008-11-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR076445A1 true AR076445A1 (es) | 2011-06-15 |
Family
ID=42170747
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090104420A AR076445A1 (es) | 2008-11-13 | 2009-11-13 | Regeneracion de islotes pancreaticos y reversion de la diabetes por medio de la administracion in vivo de genes del factor de transcripcion de los islotes. composicion. metodo. vector. celula. |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20110287086A1 (es) |
| EP (1) | EP2350297A4 (es) |
| JP (2) | JP2012508585A (es) |
| KR (1) | KR101305931B1 (es) |
| CN (1) | CN102282263B (es) |
| AR (1) | AR076445A1 (es) |
| AU (1) | AU2009313875B2 (es) |
| BR (1) | BRPI0922030A2 (es) |
| CA (1) | CA2743668A1 (es) |
| IL (1) | IL212881A0 (es) |
| MX (1) | MX2011005047A (es) |
| NZ (3) | NZ592821A (es) |
| TW (1) | TW201029669A (es) |
| WO (1) | WO2010057045A2 (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120093914A1 (en) | 2008-11-24 | 2012-04-19 | Moma Therapeutics | Implantable liposome embedded matrix composition, uses thereof, and polycaprolactone particles as scaffolds for tissue regeneration |
| WO2011094352A1 (en) * | 2010-01-27 | 2011-08-04 | Baylor Research Institute | In-vivo non-viral gene delivery of human vascular endothelial growth factor following islet transplantation |
| AR080806A1 (es) * | 2010-03-24 | 2012-05-09 | Baylor Res Inst | Expresion del gen neurod1 en celulas epiteliales pancreaticas no endocrinas (nepec) |
| US8916534B2 (en) | 2010-10-08 | 2014-12-23 | Mina Therapeutics Limited | Methods of inducing insulin production |
| GB201205158D0 (en) | 2012-03-23 | 2012-05-09 | Univ Leeds | Apparatus and method for manipulating entrained particles |
| EP3065706A4 (en) * | 2013-11-08 | 2017-11-29 | Baylor Research Institute | Nuclear localization of glp-1 stimulates myocardial regeneration and reverses heart failure |
| EP3594348B1 (en) | 2013-11-22 | 2021-09-08 | MiNA Therapeutics Limited | C/ebp alpha short activating rna compositions and methods of use |
| JP7594298B2 (ja) * | 2018-08-01 | 2024-12-04 | オハイオ・ステイト・イノベーション・ファウンデーション | 皮膚をインスリン産生組織にリプログラミングするための組成物および方法 |
| CN113122538A (zh) * | 2021-04-15 | 2021-07-16 | 遵义医科大学附属医院 | 一种靶向敲减Rip3基因表达的shRNA、重组载体及其应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6911324B2 (en) * | 2001-10-18 | 2005-06-28 | The Regents Of The University Of California | Induction of beta cell differentiation in human cells |
| US7141240B2 (en) * | 2002-03-12 | 2006-11-28 | Cedars-Sinai Medical Center | Glucose-dependent insulin-secreting cells transfected with a nucleotide sequence encoding GLP-1 |
| US20040132679A1 (en) * | 2002-09-03 | 2004-07-08 | Baylor College Of Medicine | Induction of pancreatic islet formation |
| WO2007008220A2 (en) * | 2004-08-05 | 2007-01-18 | Baylor Research Institute | Gene or drug delivery system |
| EP1951881A4 (en) * | 2005-11-07 | 2009-03-11 | Gen Hospital Corp | METHOD AND COMPOSITIONS FOR MODULATING THE AGING OF STEM CELLS |
| CN101573445A (zh) * | 2006-09-22 | 2009-11-04 | 贝勒研究院 | 由胰腺腺泡细胞向胰岛素生成细胞的体内转化 |
-
2009
- 2009-11-13 NZ NZ592821A patent/NZ592821A/en not_active IP Right Cessation
- 2009-11-13 AU AU2009313875A patent/AU2009313875B2/en not_active Ceased
- 2009-11-13 TW TW098138716A patent/TW201029669A/zh unknown
- 2009-11-13 AR ARP090104420A patent/AR076445A1/es unknown
- 2009-11-13 NZ NZ602474A patent/NZ602474A/xx not_active IP Right Cessation
- 2009-11-13 JP JP2011536538A patent/JP2012508585A/ja active Pending
- 2009-11-13 US US13/128,840 patent/US20110287086A1/en not_active Abandoned
- 2009-11-13 NZ NZ595273A patent/NZ595273A/xx not_active IP Right Cessation
- 2009-11-13 MX MX2011005047A patent/MX2011005047A/es not_active Application Discontinuation
- 2009-11-13 BR BRPI0922030A patent/BRPI0922030A2/pt not_active IP Right Cessation
- 2009-11-13 EP EP09826868A patent/EP2350297A4/en not_active Withdrawn
- 2009-11-13 CA CA2743668A patent/CA2743668A1/en not_active Abandoned
- 2009-11-13 WO PCT/US2009/064467 patent/WO2010057045A2/en active Application Filing
- 2009-11-13 KR KR1020117013196A patent/KR101305931B1/ko not_active Expired - Fee Related
- 2009-11-13 CN CN200980154476.8A patent/CN102282263B/zh not_active Expired - Fee Related
-
2011
- 2011-05-12 IL IL212881A patent/IL212881A0/en unknown
-
2014
- 2014-02-26 US US14/191,402 patent/US20140294924A1/en not_active Abandoned
- 2014-03-17 JP JP2014053116A patent/JP5813161B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP2350297A4 (en) | 2012-05-09 |
| WO2010057045A3 (en) | 2010-09-16 |
| CA2743668A1 (en) | 2010-05-20 |
| JP2014168463A (ja) | 2014-09-18 |
| WO2010057045A2 (en) | 2010-05-20 |
| KR20110086594A (ko) | 2011-07-28 |
| WO2010057045A8 (en) | 2011-02-03 |
| AU2009313875A1 (en) | 2010-05-20 |
| NZ592821A (en) | 2012-06-29 |
| AU2009313875B2 (en) | 2013-01-10 |
| US20110287086A1 (en) | 2011-11-24 |
| NZ595273A (en) | 2012-10-26 |
| EP2350297A2 (en) | 2011-08-03 |
| BRPI0922030A2 (pt) | 2018-10-16 |
| CN102282263A (zh) | 2011-12-14 |
| KR101305931B1 (ko) | 2013-09-12 |
| CN102282263B (zh) | 2015-02-11 |
| NZ602474A (en) | 2013-02-22 |
| TW201029669A (en) | 2010-08-16 |
| JP2012508585A (ja) | 2012-04-12 |
| MX2011005047A (es) | 2011-07-29 |
| JP5813161B2 (ja) | 2015-11-17 |
| US20140294924A1 (en) | 2014-10-02 |
| IL212881A0 (en) | 2011-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR076445A1 (es) | Regeneracion de islotes pancreaticos y reversion de la diabetes por medio de la administracion in vivo de genes del factor de transcripcion de los islotes. composicion. metodo. vector. celula. | |
| Min et al. | CRISPR correction of Duchenne muscular dystrophy | |
| Oh et al. | In vivo differentiation of therapeutic insulin-producing cells from bone marrow cells via extracellular vesicle-mimetic nanovesicles | |
| Yu et al. | Exosomes secreted from GATA-4 overexpressing mesenchymal stem cells serve as a reservoir of anti-apoptotic microRNAs for cardioprotection | |
| ES2985135T3 (es) | Procedimientos para generar células ß derivadas de células madre y usos de las mismas | |
| Togel et al. | Vasculotropic, paracrine actions of infused mesenchymal stem cells are important to the recovery from acute kidney injury | |
| Huang et al. | Synthetic chemically modified mrna-based delivery of cytoprotective factor promotes early cardiomyocyte survival post-acute myocardial infarction | |
| Wang et al. | Exosomes derived from mesenchymal stromal cells pretreated with advanced glycation end product-bovine serum albumin inhibit calcification of vascular smooth muscle cells | |
| AR080029A1 (es) | Composicion de microburbujas que comprende un adn plasmidico que codifica un factor de crecimiento del endotelio vascular humano | |
| Cai et al. | Tetrahedral framework nucleic acids based small interfering RNA targeting receptor for advanced glycation end products for diabetic complications treatment | |
| Yue et al. | Engineered epidermal progenitor cells can correct diet-induced obesity and diabetes | |
| Peloso et al. | Regenerative medicine and diabetes: targeting the extracellular matrix beyond the stem cell approach and encapsulation technology | |
| Raikwar et al. | Spontaneous in vivo differentiation of embryonic stem cell-derived pancreatic endoderm-like cells corrects hyperglycemia in diabetic mice | |
| Tang et al. | The enhancement of endothelial cell therapy for angiogenesis in hindlimb ischemia using hyaluronan | |
| Chung et al. | Mesenchymal stem cell and MicroRNA therapy of musculoskeletal diseases | |
| Pileggi et al. | MicroRNAs in islet immunobiology and transplantation | |
| Yao et al. | Mesenchymal stem cells as novel micro‐ribonucleic acid delivery vehicles in kidney disease | |
| Oh et al. | Direct differentiation of bone marrow mononucleated cells into insulin producing cells using pancreatic β-cell-derived components | |
| Phillips et al. | Genetic modification of stem cells for cardiac, diabetic, and hemophilia transplantation therapies | |
| Viswanathan et al. | Status of stem cell based clinical trials in the treatment for diabetes | |
| Cao et al. | Cell therapy for muscle regeneration and repair | |
| Sabouri et al. | The role of microRNAs in the induction of pancreatic differentiation | |
| KR101671776B1 (ko) | Asgr1 또는 자칼린을 이용한 간섬유화 또는 간경화 치료용 조성물 | |
| Rajput et al. | Advances in the treatment of kidney disorders using mesenchymal stem cells | |
| Sabet Sarvestani et al. | Indirect co‐culture of islet cells in 3D biocompatible collagen/laminin scaffold with angiomiRs transfected mesenchymal stem cells |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |